Sugi Predict

Sugi Predict / Compounds / SCHEMBL381572

SCHEMBL381572

SCHEMBL381572

c1ccc([C@H]2CCCNC2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SLC18A3 Q16572 1/20 0.59
▸ SIGMAR1 Q99720 1/20 0.59
▸ DRD2 P14416 1/20 0.59
▸ DRD3 P35462 1/20 0.59
▸ KCNH2 Q12809 2/20 0.53
▸ HTR2A P28223 1/20 0.53
▸ HTR2C P28335 1/20 0.53
▸ HTR3A P46098 1/20 0.52
▸ KDM1A O60341 1/20 0.51
▸ MAOB P27338 1/20 0.51
▸ JAK3 P52333 1/20 0.50
▸ CYP2D6 P10635 1/20 0.49
▸ SLC6A2 P23975 1/20 0.49
▸ SLC6A4 P31645 1/20 0.49
▸ SLC6A3 Q01959 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL383031 1.00 SLC18A3 (0.59) SLC18A3SIGMAR1DRD2DRD3KCNH2
Benzene SCHEMBL28198364 1.00 SLC18A3 (0.59) SLC18A3SIGMAR1DRD2DRD3KCNH2
SCHEMBL4280 1.00 SLC18A3 (0.59) SLC18A3SIGMAR1DRD2DRD3KCNH2
Hydrochloric Acid SCHEMBL1765272 0.98 DRD2 (0.57) SLC18A3SIGMAR1DRD2DRD3KCNH2
Hydrochloric Acid SCHEMBL31233227 0.98 DRD2 (0.57) SLC18A3SIGMAR1DRD2DRD3KCNH2
SCHEMBL3701789 0.94 SLC18A3 (0.57) SLC18A3SIGMAR1DRD2DRD3KCNH2
Hydrochloric Acid SCHEMBL3689510 0.92 SLC18A3 (0.55) SLC18A3SIGMAR1DRD2DRD3KCNH2
SCHEMBL28296875 0.91 DRD2 (0.51) SLC18A3SIGMAR1DRD2DRD3KCNH2
Pyridine SCHEMBL11331327 0.89 DRD2 (0.50) SLC18A3SIGMAR1DRD2DRD3KCNH2
SCHEMBL495697 0.89 SLC18A3 (0.75) SLC18A3SIGMAR1HTR3AJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109810047-A (R) synthetic method of the chiral intermediate of -3- Phenylpiperidine or/and (S) -3- Phenylpiperidine and Ni Lapani 上海博邦医药科技有限公司 2019-05-28 — — CN claimed
CN-108203404-A (R) synthetic method of -3- Phenylpiperidines or/and the chiral intermediate of (S) -3- Phenylpiperidines and Ni Lapani 上海博邦医药科技有限公司 2018-06-26 — — CN claimed
EP-4618755-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN Larkspur Biosciences, Inc. (US) 2025-09-24 — — EP disclosed
WO-2024107746-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN LARKSPUR BIOSCIENCES (US) 2024-05-23 — — WO disclosed
CN-117402124-A Aryl sulfonamide compound and anti-influenza application thereof 中国医学科学院医药生物技术研究所 2024-01-16 — — CN disclosed
US-20230295197-A1 STAT5 and STAT6 Degraders and Uses Thereof REGENTS OF THE UNIV OF MICHICAN (US) 2023-09-21 — — US disclosed
US-20230227428-A1 AMIDO COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-07-20 — — US disclosed
EP-3498701-B1 PRMT5 INHIBITORS AND USES THEREOF EPIZYME INC (US) 2023-02-22 — — EP disclosed
EP-3287441-B1 ACYLATED 4-AMINOPIPERIDINES AS INHIBITORS OF SERINE PALMITOYLTRANSFERASE TAKEDA PHARMACEUTICALS CO (JP) 2021-06-09 — — EP disclosed
US-20200325128-A1 COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER Argonaut Therapeutics Limited (GB) 2020-10-15 — — US disclosed
US-10758534-B2 Modulators of cystic fibrosis transmembrane conductance regulator VERTEX PHARMACEUTICALS INCORPORATED (US) 2020-09-01 — — US disclosed
EP-2346853-A2 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE Schering Corporation (US) 2011-07-27 — — EP disclosed
US-20100317646-A1 COMPOUNDS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-12-16 — — US disclosed
WO-2010106333-A1 COMPOUNDS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-09-23 — — WO disclosed
WO-2010059606-A2 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE SCHERING CORPORATION (US) 2010-05-27 — — WO disclosed
US-20080207735-A1 1-Amino Linked Compounds ELI LILLY AND COMPANY 2008-08-28 — — US disclosed
EP-1910317-A1 1-AMINO LINKED COMPOUNDS Eli Lilly and Company (US) 2008-04-16 — — EP disclosed
US-20070191429-A1 PPAR ACTIVATORS PFIZER INC. (US) 2007-08-16 — — US disclosed
US-7199243-B2 Piperidine compounds useful as PPAR activators PFIZER INC. (US) 2007-04-03 — — US disclosed
WO-2007015805-A1 1-AMINO LINKED COMPOUNDS ELI LILLY AND COMPANY (US) 2007-02-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207735-A1 1-Amino Linked Compounds DPP4, DPP3, DPP9 SLC18A3 1288/4885SIGMAR1 281/4885DRD2 277/4885
US-20070191429-A1 PPAR ACTIVATORS PPARA, PPARG, PPARD SLC18A3 3657/4885SIGMAR1 1528/4885DRD2 2900/4885
US-20230227428-A1 AMIDO COMPOUNDS RIPK1, RIPK3, MLKL SLC18A3 4705/4885SIGMAR1 2113/4885DRD2 3854/4885
US-20230295197-A1 STAT5 and STAT6 Degraders and Uses Thereof STAT6, STAT5B, STAT5A SLC18A3 4882/4885SIGMAR1 1981/4885DRD2 3804/4885
US-20200325128-A1 COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER PRMT5, PRMT6, PRMT1 SLC18A3 2282/4885SIGMAR1 4334/4885DRD2 4685/4885
US-20100317646-A1 COMPOUNDS CBR3, CNR1, HCAR3 SLC18A3 2336/4885SIGMAR1 116/4885DRD2 213/4885
US-10758534-B2 Modulators of cystic fibrosis transmembrane conductance regulator CFTR, SCNN1B, SLC26A4 SLC18A3 950/4885SIGMAR1 764/4885DRD2 2964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.